United Kingdom· GB-APID-38140511000001104
Incruse Ellipta 55micrograms/dose dry powder inhaler
A medicinal product containing umeclidinium bromide, registered in United Kingdom by DE Pharmaceuticals.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Umeclidinium bromide
- Manufacturer
- DE Pharmaceuticals
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Umeclidinium bromide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINCRUSE ELLIPTAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumElebrato Ellipta 92 µg/dose - 22 µg/doseGlaxoSmithKline Trading Services
- SpainINCRUSE ELLIPTA 55 mcg POLVO PARA INHALACION UNIDOSISGlaxosmithkline Trading Services Limited
- FinlandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- NetherlandsIncruse Ellipta 55 microgram inhalatiepoeder, voorverdeeldGlaxoSmithKline Trading Services Limited
- United StatesIncruse ElliptaGlaxoSmithKline LLC
- SwitzerlandIncruse Ellipta
- IrelandIncruse Ellipta 55 micrograms inhalation powder, pre-dispensedGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Incruse Ellipta, Rolufta Ellipta
- Liechtenstein · Incruse Ellipta, Rolufta Ellipta
- Norway · Incruse Ellipta, Rolufta Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed80e3a4-1b0f-4dbf-b9c1-accd7d56a2b5 GET /v1/drugs/ed80e3a4-1b0f-4dbf-b9c1-accd7d56a2b5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "38140511000001104",
"desc": "Incruse Ellipta 55micrograms/dose dry powder inhaler (DE Pharmaceuticals)",
"form": "Inhalation powder",
"vpid": "27890611000001109",
"source": "dmd",
"vtm_id": "27896111000001103",
"strength": "65 microgram",
"substance": "Umeclidinium bromide",
"ingredient": "Umeclidinium bromide",
"supplier_code": "2268901000001109"
}See everything about umeclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.